That's fine if they're placebo patients who crossed over to the vaccine. It would be a strong indication that the vaccine can be administered latter in treatment and still be effective. I really don't think we'll find that any placebo patients who didn't cross over are long term survivors.
We have a friend who has a close friend with GBM who's pretty far advanced. He's being treated at Cedars and we've made them aware of DCVax-L but I don't believe it's available anywhere if his tumor was properly preserved. I've suggested they contact UCLA to see if one of their combination trials might apply, but I doubt it. I don't believe the patient could be moved to England even if they could be considered for compassionate use there, but I have no idea how sick a patient must be to be beyond all hope, he probably is there already. I don't know him personally, but their description of him makes me think that there is little that can be done besides keeping him as comfortable as possible.
Gary
Market Data 
Markets 
AI
